HomeCompareSBMIF vs PFE

SBMIF vs PFE: Dividend Comparison 2026

SBMIF yields 1663.89% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SBMIF wins by $1811853414.11M in total portfolio value
10 years
SBMIF
SBMIF
● Live price
1663.89%
Share price
$0.12
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1811853414.16M
Annual income
$1,620,292,985,292,741.00
Full SBMIF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — SBMIF vs PFE

📍 SBMIF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSBMIFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SBMIF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SBMIF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SBMIF
Annual income on $10K today (after 15% tax)
$141,430.95/yr
After 10yr DRIP, annual income (after tax)
$1,377,249,037,498,829.80/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, SBMIF beats the other by $1,377,249,037,476,509.80/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SBMIF + PFE for your $10,000?

SBMIF: 50%PFE: 50%
100% PFE50/50100% SBMIF
Portfolio after 10yr
$905926707.11M
Annual income
$810,146,492,659,499.90/yr
Blended yield
89.43%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

SBMIF
No analyst data
Altman Z
-0.8
Piotroski
2/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SBMIF buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSBMIFPFE
Forward yield1663.89%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$1811853414.16M$49.6K
Annual income after 10y$1,620,292,985,292,741.00$26,258.71
Total dividends collected$1798045071.15M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SBMIF vs PFE ($10,000, DRIP)

YearSBMIF PortfolioSBMIF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$177,089$166,389.35$9,153$693.39+$167.9KSBMIF
2$2,943,297$2,753,811.42$8,593$849.25+$2.93MSBMIF
3$45,924,529$42,775,201.54$8,336$1,066.78+$45.92MSBMIF
4$672,901,240$623,761,993.51$8,437$1,384.80+$672.89MSBMIF
5$9,261,653,813$8,541,649,486.09$9,013$1,875.40+$9261.64MSBMIF
6$119,784,032,270$109,874,062,690.33$10,306$2,680.72+$119784.02MSBMIF
7$1,456,241,434,338$1,328,072,519,808.98$12,820$4,101.38+$1456241.42MSBMIF
8$16,647,595,595,234$15,089,417,260,492.14$17,673$6,826.70+$16647595.58MSBMIF
9$179,028,438,194,435$161,215,510,907,534.75$27,543$12,591.86+$179028438.17MSBMIF
10$1,811,853,414,160,787$1,620,292,985,292,741.00$49,560$26,258.71+$1811853414.11MSBMIF

SBMIF vs PFE: Complete Analysis 2026

SBMIFStock

Stratabound Minerals Corp. engages in the exploration and evaluation of mineral resource properties in North America. The company primarily explores for lead, zinc, silver, copper, gold, and cobalt deposits. Its flagship project is the Fremont Gold project covering approximately 51 acres of land in Mariposa County, California; and the Dingman Gold project consists of 19 mineral claims that covers approximately 200.6 hectares located in the north of Belleville, Ontario. The company is also holds 100% interest in the McIntyre Brook Project located in New Brunswick; and Bathurst Group property comprising approximately 158 units and one mining lease in the Bathurst base metal mining camp in New Brunswick, Canada, as well as holds option to acquire 100% interest in the Golden Culvert property that covers an area of 83.8 square kilometers located in the southeast Yukon Territory. Stratabound Minerals Corp. is based in Toronto, Canada.

Full SBMIF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this SBMIF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SBMIF vs SCHDSBMIF vs JEPISBMIF vs OSBMIF vs KOSBMIF vs MAINSBMIF vs JNJSBMIF vs MRKSBMIF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.